Scientific Advisory Board
Dr. Gianni Gromo
Dr. Gromo is a world-renowned expert with a proven track record in drug development and discovery. Throughout his long career at Roche, he has held key positions including Head of Global Cardiovascular & Metabolic Research, Chair of the Global Metabolic & Vascular Management Discovery Team, and as Head of Discovery Research and Non Clinical Development at the Basel Headquarters in Switzerland. Dr. Gromo was also a member of the Pharma Committee of China and served on the faculty of the University of Minnesota. He also serves as a Scientific Advisor at various companies including CCSIRO and the Baker Institute in Australia.
Prof. Itamar Shalit
Prof. Shalit is an expert in infectious diseases, actively involved in various national committees of the Israeli Ministry of Health. He was awarded Certificate of Appreciation Declaration by the World Health Organization for his role in eradicating poliomyelitis in Israel. In the past, Prof. Shalit also served as the Director General of Schneider Children’s Hospital and of Carmel Hospital, and was the Chairman of the Israeli Society for Infectious Diseases. Prof. Shalit serves as a Member of the Scientific Advisory Board at BioLineRx, Ltd., NasVax, and Therapix Biosciences Ltd. Prof. Shalit served as a Member of the Scientific Advisory Board at Teva Innovative Ventures until 2011. Currently, he serves as CEO of the Galilee Biomedical Research Administration. Prof. Shalit holds an MD from Tel Aviv University and an MPA from Harvard University.
Dr. Hadar Ron
Dr. Ron has an extensive track record in the healthcare, insurance, legal and financial sectors. She is the founding partner of Israel Healthcare Ventures (IHCV) and serves as Chairman and board member of various healthcare companies, including Yissum and the Momentum Fund. Dr. Ron is a physician and attorney by education, with MD and LLB degrees from Tel Aviv University.
Dr. Aharon Schwartz
Dr. Schwartz had an impressive career at Teva Pharmaceutical Industries, having served as VP of multiple divisions including Innovative Ventures, Strategic Business Planning and Global Products. He currently serves as Chairman of innovative companies including BiolineRX, CBI, DPharm, BioCancell, MediWound and CureTech, and board member of Protalix. Dr. Schwartz holds a PhD in Organic Chemistry from the Weizmann Institute.